MHRA Approves First Needle-Free Adrenaline Nasal Spray for Anaphylaxis in the UK

MHRA Approves First Needle-Free Adrenaline Nasal Spray for Anaphylaxis in the UK

On 18 July 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved a major breakthrough in allergy care: the adrenaline (epinephrine) nasal spray, EURneffy.

This is the first-ever needle-free treatment for anaphylaxis in the UK, giving patients and carers an alternative to traditional adrenaline auto-injectors.

What is Anaphylaxis?

Anaphylaxis is a severe, sudden, and sometimes life-threatening allergic reaction.
It can cause:

  • A dangerous drop in blood pressure
  • Difficulty breathing
  • The need for immediate emergency treatment

Adrenaline has long been the standard treatment. Until now, it has only been available through auto-injectors like the EpiPen.

Why This Approval Matters

The introduction of a nasal spray makes emergency treatment more accessible, especially for people who may struggle to use a needle in a crisis.

Key points:

  • Suitable for adults and children over 30kg (about 66 pounds)
  • Provides a full 2mg dose in one spray
  • Can be used even with a blocked or congested nose

Important Guidance for Patients

  • Always carry two sprays, in case a second dose is needed
  • Make sure family, friends, and carers know how to use them
  • Do not press the plunger until the spray is in the nostril – it is single use
  • Remember: auto-injectors remain essential and should still be carried if prescribed

Safety and Monitoring

Like all new medicines, the adrenaline nasal spray will be closely monitored for safety and effectiveness.

If you suspect side effects, you can report them via the MHRA Yellow Card scheme.

A Step Forward in Allergy Care

Julian Beach, Interim Executive Director of Healthcare Quality and Access at the MHRA, said:

“Patient safety is our top priority, which is why we’re pleased to approve the first needle-free nasal spray formulation of adrenaline for the emergency treatment of anaphylaxis in the UK. While this represents an important new option, adrenaline auto-injectors remain a vital and potentially life-saving treatment.”

This approval was made through the International Recognition Procedure (IRP), which uses expertise from trusted global regulators to benefit UK patients.

Find Out More

You can read the full announcement here:
👉 MHRA approves adrenaline nasal spray – the first needle-free emergency treatment for anaphylaxis in the UK

Related Posts